EPHA5 and cancer: Emerging molecular variants such as Bruton tyrosine kinase (BTK) and Ephrin type-A receptor 5 (EPHA5) promote metabolic reprogramming, drug resistance, and metastasis [9], and cancer stem cells’ (CSCs) persistence contributes to adaptation to therapy and recurrence [10].